YZYBIO-B: VOLUNTARY ANNOUNCEMENT -THE FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OFM701, A BISPECIFIC ANTIBODY FOR TREATMENT OF MALIGNANTASCITES

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.